PWR
76
2
MET
45
5
CAG
47
3
PSX
47
5
ABBV
40
-8
XRAY
37
2
PH
77
3
ILMN
38
2
AAL
32
-4
MLM
76
2
URBN
70
7
WDC
58
3
HAL
50
-4
VZ
30
3
PXD
48
-6
MMC
48
-3
AVB
62
-2
CTAS
55
2
BLK
49
3
LRCX
59
3
PWR
76
2
MET
45
5
CAG
47
3
PSX
47
5
ABBV
40
-8
XRAY
37
2
PH
77
3
ILMN
38
2
AAL
32
-4
MLM
76
2
URBN
70
7
WDC
58
3
HAL
50
-4
VZ
30
3
PXD
48
-6
MMC
48
-3
AVB
62
-2
CTAS
55
2
BLK
49
3
LRCX
59
3
Financhill
Back

4D Molecular Therapeutics 10K Form

Sell
16

FDMT
4D Molecular Therapeutics

Last Price:
23.21
Seasonality Move:
-11.17%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-03-25 10K FDMT/4D Molecular Therapeutics Annual

Receive FDMT News And Ratings

See the #1 stock for the next 7 days that we like better than FDMT

FDMT Financial Statistics

Sales & Book Value

Annual Sales: $20.72M
Cash Flow: $-25.2M
Price / Cash Flow: 0
Annual Sales: $7.15
Price / Book: 3.76

Profitability

EPS (TTM): -2.66000
Net Income (TTM): $-100.84M
Gross Margin: --
Return on Equity: -35.69%
Return on Assets: -32.32%

4D Molecular Therapeutics Earnings Forecast

Key 4D Molecular Therapeutics Financial Ratios

  • The Research & Development expenses have been 468.54% of Revenue.
  • The Net Earning history of FDMT is -486.59% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

4D Molecular Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FDMT
CUSIP: 35104E
Website: 4dmoleculartherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 15.65
Quick Ratio: 15.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FDMT Technical Analysis vs Fundamental Analysis

Sell
16
4D Molecular Therapeutics (FDMT) is a Sell

Is 4D Molecular Therapeutics a Buy or a Sell?